Aminoglycoside - Extended Interval Dosing and Nomograms

Key Points

• Extended-interval dosing exploits concentration-dependent killing and the aminoglycoside post-antibiotic effect.
• Use only the dose and sampling window validated for the institution's nomogram.
• Choose dosing weight intentionally, especially in obesity or low body weight.
• Renal function primarily drives the interval and must be reassessed during treatment.
• A mistimed random concentration should not be plotted as if it were valid.
• Pregnancy, dialysis, unstable renal function, and certain synergy indications usually require alternative dosing strategies.
• Minimize duration once culture results permit de-escalation because nephrotoxicity and ototoxicity are cumulative risks.
• New tinnitus, hearing loss, vertigo, or renal decline should trigger prompt reassessment.

Algorithm

1. Confirm a clinical indication for aminoglycoside therapy and review local susceptibility data.
2. Calculate the protocol-defined dosing weight and baseline renal function.
3. Exclude patients who do not fit the extended-interval protocol.
4. Administer the protocol dose and record the exact infusion time.
5. Obtain a random serum level in the validated post-dose window and select interval from the nomogram.
6. Monitor renal function, urine output, and concurrent nephrotoxins.
7. Repeat levels when required by protocol or when pharmacokinetics change.
8. Stop or transition to a less toxic effective antibiotic as soon as clinically appropriate.

Clinical Synopsis & Reasoning

Aminoglycosides such as gentamicin, tobramycin, and amikacin kill susceptible aerobic gram-negative bacteria in a concentration-dependent manner. A high peak relative to the organism MIC improves bactericidal activity, while the post-antibiotic effect suppresses bacterial growth even after serum concentrations fall. Extended-interval dosing uses these properties by administering a larger dose, commonly once daily or at a longer interval, and allowing the concentration to fall to a very low level before the next dose.

The dosing weight must be selected deliberately. Actual body weight is commonly used in non-obese patients, while adjusted body weight is often used when obesity would otherwise overestimate the aminoglycoside distribution volume. Underweight patients require a different approach, and local pharmacy protocols should define formulas and maximum doses. Kidney function determines the interval more than the initial concentration-dependent dose in many nomogram systems.

A nomogram such as the Hartford approach is not a general 'aminoglycoside level chart.' It is validated only for a particular dose strategy and sampling window. A concentration drawn at the wrong time or after a nonmatching dose cannot be plotted reliably. Many protocols obtain one random level several hours after the first dose and use the result to select a 24-, 36-, or 48-hour interval. The exact dose, sampling window, and nomogram boundaries vary by institution.

Extended-interval dosing is poorly suited to patients with rapidly changing kidney function, major burns, ascites or large fluid shifts, pregnancy, dialysis, cystic fibrosis protocols that use different pharmacokinetics, or indications requiring traditional synergistic dosing such as selected enterococcal endocarditis regimens. These patients require individualized pharmacokinetic monitoring rather than forced placement on a standard nomogram.

Treatment Strategy & Disposition

Before the first dose, confirm indication, expected pathogens, local susceptibility, body size, baseline creatinine, urine output, hearing/vestibular history, neuromuscular disease, pregnancy status when relevant, and concurrent nephrotoxins. Aminoglycosides should not be continued simply because they were part of empiric sepsis coverage; culture results and source control should be reviewed early to minimize unnecessary exposure.

Administer the institution's weight-based extended-interval dose, document infusion time, and draw the random concentration in the exact validated window. Plot the true elapsed hours from the beginning or end of infusion according to the nomogram instructions. If the value lies above the chart, do not improvise a longer interval without reviewing renal function and protocol; pharmacy-guided individualized dosing may be safer.

Monitor serum creatinine and urine output during therapy. Longer courses increase nephrotoxicity and ototoxicity risk, particularly with concurrent vancomycin, loop diuretics, cisplatin, contrast, or critical illness. Ask about tinnitus, hearing loss, vertigo, and imbalance when exposure is prolonged or symptoms develop. Formal audiometry is considered for prolonged therapy, high cumulative exposure, or high-risk patients.

De-escalate promptly when a less toxic active agent is available. If ongoing aminoglycoside therapy is essential, repeat level assessment according to protocol and whenever renal function changes. Severe infection with altered pharmacokinetics may require individualized peak/AUC or multiple-level monitoring rather than a one-point nomogram.

Epidemiology / Risk Factors

• Aminoglycosides remain important for selected severe gram-negative infections and as part of some combination regimens.
• Use has declined in many settings because safer active alternatives are available.
• Nephrotoxicity risk rises with duration, cumulative exposure, critical illness, and concurrent nephrotoxins.
• Ototoxicity can be cochlear or vestibular and may be irreversible.

Investigations

Common Exclusions

Pharmacology

Prognosis / Complications

• Short, appropriately monitored courses are often tolerated without permanent toxicity.
• Acute kidney injury is usually nonoliguric and may improve after drug discontinuation, but recovery can be delayed.
• Ototoxic injury may persist despite stopping the medication.
• Outcome in severe infection depends primarily on timely active therapy, source control, and adequacy of overall antimicrobial treatment.

Patient Education / Counseling

• Explain why a blood level must be drawn at a specific number of hours after the dose.
• Tell patients to report ringing in the ears, hearing change, dizziness, imbalance, reduced urine output, or swelling.
• Review OTC NSAIDs and other nephrotoxic drugs during longer courses.
• Clarify that a 'once-daily' regimen may actually become every 36 or 48 hours when renal clearance is reduced.
• For outpatient therapy, ensure laboratory timing and infusion schedules are coordinated rather than left to the patient to reconcile.

Notes

The nomogram is a protocol tool, not a pharmacology law. Hospitals use different extended-interval doses and sampling instructions, and a concentration cannot be interpreted correctly without knowing which protocol generated it.

The stewardship goal is to use aminoglycosides when their rapid bactericidal activity adds value, then discontinue them as soon as safer definitive therapy is established. Prolonging empiric aminoglycoside therapy after cultures identify a suitable alternative creates toxicity without improving source control.

References

1. ASHP aminoglycoside dosing resources — Link
2. IDSA guidance for gram negative infections — Link